Key Highlights

  • Davion Healthcare (NASDAQ:DAVI) was trading up 20.61% at USD 1.58 on Friday, November 6, 2026, implying a prior close near USD 1.31 (calculated from the screener move).
  • Shares traded at USD 4.04 on October 26, 2026, down 32.67% from a USD 6.00 prior close, so the stock is now about 61% below that level (calculated).
  • On October 29, 2026 the company agreed to buy Healthcare Stat Homecare for USD 13.5 million, made up of USD 8 million in cash and USD 5.5 million in shares.
  • The stock component is priced at USD 13 per share, about 423,000 shares (calculated), a level far above the current USD 1.58 quote.

A Bounce After a Sharp Post-Debut Slide

Davion Healthcare (NASDAQ:DAVI) was trading up 20.61% at USD 1.58 on Friday, November 6, 2026. No company announcement dated November 5 or 6 that explains the move was found. The ordinary shares were expected to begin trading on the Nasdaq Global Market on October 22, 2026, and on October 26 they were quoted at USD 4.04 after a USD 6.00 prior close. The company develops non-invasive health monitoring technology, led by BreastCheck, an FDA-registered at-home breast health screening test that looks for abnormalities through changes in breast temperature. Calculated, the screener price is about 61% below the October 26 quote.

The USD 13.5 Million Home Care Acquisition

In a release on October 29, 2026, the company announced an agreement dated October 27 to acquire Healthcare Stat Homecare, a Philadelphia home healthcare provider. The price is USD 13.5 million, with USD 8 million in cash and USD 5.5 million in shares at USD 13 each, and completion is expected on or before December 31, 2026. The seller reported unaudited 2025 gross receipts of about USD 11.6 million and ordinary Business income of about USD 1.9 million. Management called it the first of a planned programme of acquisitions of profitable healthcare businesses over the coming year. The company also named Glenn Williams chief executive and Jeremy North chief operating officer. The seller offers skilled nursing, home health aide and rehabilitation care, including wound care, dementia and diabetes care and telehealth. Davion said it also plans to explore using its monitoring technologies in home care.

Valuation Gap and Thin-Trading Risk

Published market data put the Market Value at USD 101 million with 25 million shares outstanding when the stock was at USD 4.04, which implies roughly USD 39.5 million at USD 1.58 (calculated). The USD 8 million cash payment is therefore a large share of the current value, and the USD 13 share price used in the deal is far from the market. The company is newly listed, so a small number of trades can move the price, spreads can be wide and quoted moves can reverse. No Revenue figures for Davion itself were found. The cash needs also matter: no cash balance or financing for the USD 8 million payment was found, so the funding is unconfirmed.

Where Things Stand

The rise looks like a rebound after a sharp post-debut decline, not a reaction to confirmed news. Davion Healthcare (NASDAQ:DAVI) was trading up 20.61% at USD 1.58 on Friday, November 6, 2026, with the Healthcare Stat Homecare deal and the new management structure as the main company developments found. Watch for completion by December 31, 2026, how the USD 8 million cash payment is funded and the first reported results. Management has said more acquisitions are planned over the coming year.